SCHEMBL4670705

SCHEMBL4670705

O=C(Cc1cc(Cc2ccccc2F)co1)C(=O)c1nn[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
CES1 P23141 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
AR P10275 1/20 0.33
CXCR3 P49682 4/20 0.33
MMEL1 Q495T6 2/20 0.32
ACHE P22303 1/20 0.32
MPO P05164 1/20 0.31
ALDH1A1 P00352 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HCAR3 P49019 1/20 0.31
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
MME P08473 1/20 0.31
TDP1 Q9NUW8 1/20 0.30
FFAR2 O15552 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673700 0.92 PTGDR2 (0.35) PTPN1PTGDR2CES1NCEH1AR
SCHEMBL4676995 0.86 CES1 (0.42) PTGDR2CES1NCEH1ARMMEL1
SCHEMBL4679605 0.84 TDP1 (0.34) PTGDR2CES1NCEH1CXCR3MMEL1
SCHEMBL4675471 0.83 FFAR2 (0.40) PTGDR2CES1NCEH1ACHETDP1
SCHEMBL4670908 0.83 PTPN1 (0.35) PTPN1ARALDH1A1HCAR3
SCHEMBL4674402 0.83 PTGDR2 (0.35) PTGDR2CES1NCEH1ARCXCR3
SCHEMBL4675276 0.81 FFAR2 (0.35) CES1NCEH1CXCR3ALDH1A1L3MBTL1
SCHEMBL4673451 0.81 PTPN1 (0.35) PTPN1PTGDR2CES1NCEH1CXCR3
SCHEMBL4670733 0.81 AR (0.36) PTGDR2CES1NCEH1ARCXCR3
SCHEMBL4675417 0.81 CES1 (0.32) CES1NCEH1FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTPN1 2715/4885PTGDR2 4591/4885CES1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.